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Abstract  
 
 
Aims: Cyclic adenosine monophosphate (cAMP) regulates cardiac excitation-contraction 
coupling by acting in microdomains associated with sarcolemmal ion channels. However, local 
real time cAMP dynamics in such microdomains has not been visualized before. We sought to 
directly monitor cAMP in a microdomain formed around sodium-potassium ATPase (NKA) in 
healthy and failing cardiomyocytes and to better understand alterations of cAMP 
compartmentation in heart failure.  
 
Methods and Results: A novel Förster resonance energy transfer (FRET)-based biosensor 
termed PLM-Epac1 was developed by fusing a highly sensitive cAMP sensor Epac1-camps to 
the C-terminus of phospholemman (PLM). Live cell imaging in PLM-Epac1 and Epac1-camps 
expressing adult rat ventricular myocytes revealed extensive regulation of NKA/PLM 
microdomain associated cAMP levels by b2-adrenoceptors (b2-ARs). Local cAMP pools 
stimulated by these receptors were tightly controlled by phosphodiesterase (PDE) type 3. In 
chronic heart failure following myocardial infarction, dramatic reduction of the microdomain-
specific b2-AR/cAMP signals and b2-AR dependent PLM phosphorylation was accompanied 
by a pronounced loss of local PDE3 and an increase in PDE2 effects.    
 
Conclusions: NKA/PLM complex forms a distinct cAMP microdomain which is directly 
regulated by b2-ARs and is under predominant control by PDE3. In heart failure, local changes 
in PDE repertoire result in blunted b2-AR signaling to cAMP in the vicinity of PLM. 
   
 
 
Key words: cAMP, phospholemman, phosphodiestarase, FRET, heart failure  
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Introduction 
 
3’,5’-cyclic adenosine monosphosphate (cAMP) as an ubiquitous second messenger regulates 
cardiomyocyte function by acting in discrete subcellular microdomains. Such microdomains 
are formed for example around ion channels participating in excitation-contraction (EC) 
coupling and involve a set of differentially localized receptors, cAMP-dependent protein kinase 
(PKA) with its anchoring proteins, and cAMP hydrolyzing enzymes phosphodiesterases 
(PDEs) which are crucial for spatial confinement of cyclic nucleotide gradients in cells1, 2. 
Functionally distinct cAMP microdomains have previously been described in caveolin-rich 
membrane structures3, various subsarcolemmal locations4 and around sarcoplasmic reticulum 
calcium ATPase5. However, local cAMP dynamics in any microdomain directly associated with 
a sarcolemmal ion channel involved in EC coupling and its changes in cardiac disease have 
not been studied before.   
 
An important cAMP microdomain might be associated with the sodium-potassium ATPase 
(NKA), a sarcolemmal pump which, as the predominant Na+ efflux mechanism in 
cardiomyocytes, maintains the transmembrane Na+ gradient. This gradient is essential not only 
for a variety of Na-dependent membrane transporters but also for the rapid upstroke of action 
potential upon depolarization6, 7. Subsequent elevation of intracellular Ca2+ triggers cell 
contraction followed by the diastolic Ca2+ extrusion via the sodium-calcium exchanger (NCX) 
in its forward mode which in turn is promoted by the transmembrane Na+ gradient8. Therefore, 
NKA activity orchestrates calcium cycling and EC coupling. In heart failure, an increase in 
intracellular Na+, in part due to a decline in NKA activity, dissipates this Na+ gradient and hence 
contributes to altered Ca cycling, diastolic dysfunction, arrhythmias and changes in 
mitochondrial metabolism9-12.    
 
Phospholemman (PLM, also known as FXYD1) is a 72 amino acid transmembrane muscle cell 
protein13-15 which forms a stable complex with NKA16, 17. The cytosolic C-terminus of PLM bears 
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at least three different phosphorylation sites, one of them Ser68 can be phosphorylated by the 
cAMP-dependent protein kinase (PKA) and protein kinase C18-20. PLM tonically inhibits NKA, 
and PLM phosphorylation by PKA leads, via a conformational change occurring without a 
dissociation, to an increase of NKA activity (its sodium affinity and transport kinetics), thereby 
lowering intracellular sodium load during increases in heart rate under b-adrenoceptor (b-AR) 
stimulation21. Conversely, hypo-phosphorylation of PLM, as occurs in heart failure, 
exacerbates contractile dysfunction, increases Na+ overload and promotes myocardial 
remodeling22. Despite the importance of PLM phosphorylation in both normal and 
pathophysiology, local cAMP dynamics in this critical microdomain has not been directly 
investigated. 
 
Here, we developed a novel targeted Förster resonance energy transfer (FRET)-based cAMP 
biosensor to monitor real time cAMP dynamics in the vicinity of the NKA/PLM complex. FRET 
measurements uncovered tight regulation of this microdomain by the b2-AR/cAMP/PKA and 
local pools of PDE3, which was lost in heart failure. These data provide a molecular basis for 
better understanding of disease-associated local signaling changes and may help develop new 
therapies to prevent sodium overload in heart failure.  
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Methods 
 
Detailed methods section is available in the Supplementary Material. 
 
Chemicals. BAY 60-7550 was from Santa Cruz. Cilostamide, rolipram, (-) isoproterenol (ISO), 
forskolin, CGP20712A and ICI118551 were purchased from Sigma.  3-isobutyl-1-
methylxanthine (IBMX) was from Applichem. All other chemicals were from Sigma, unless 
stated otherwise. 
 
Sensor construction. Full-length canine PLM sequence lacking the stop codon was fused via 
a flexible linker encoding the KRSRAQASNSAVDGTPVATG amino acid sequence to the N-
terminus of Epac1-camps23. The adenovirus generation is performed using the Gateway® 
Cloning system (Life Technologies) and in accordance with the manufacturer´s instructions. 
 
FRET-based cAMP measurements in cardiomyocytes. Rats were anesthetized by 
isoflurane inhalation and sacrificed by cervical dislocation. Adult rat ventricular myocytes 
(ARVMs) were isolated by enzymatic Langendorff perfusion, transduced for 48 h with Epac1-
camps or PLM-Epac1 adenoviruses and subjected to FRET measurements as described24,24. 
Imaging was performed at room temperature in the buffer A containing in mmol/L: NaCl 144, 
KCl 5.4, MgCl2 1, CaCl2 1, HEPES 10, pH=7.3. Compounds were diluted in the same buffer 
and applied onto cells cumulatively if not stated otherwise. 
 
Myocardial infarction (MI) chronic heart failure model. All animal experiments were 
performed in accordance with Guide for the Care and Use of Laboratory Animals published by 
the U.S. National Institutes of Health under assurance number A5634-01. All surgical 
procedures and perioperative management conformed to the UK Animals (Scientific 
Procedures) Act 1986 and were approved by the Animal Welfare and Ethical Review Body 
(AWERB) Committee of Imperial College London. Adult male Sprague-Dawley rats (250–300 
g) underwent proximal coronary ligation to induce MI under isoflurane anaesthesia as 
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previously described25, 26. Righting reflex was used to monitor the adequacy of anaesthesia. 
For analgesia, metamizole (300 mg/kg/day in drinking water 3 days prior and 7 days after 
surgery) and buprenorphine (0.05 mg/kg subcutaneously, 30 min prior to and every 8 h during 
7 days after surgery) were used. Rats were functionally characterized by echocardiography 
and sacrificed 16 weeks after MI by cervical dislocation in isoflurane anaesthesia for 
cardiomyocyte isolation. Echocardiographic and functional parameters of the rats used in this 
study have been previously described27. 
 
Statistics. Normal distribution was tested by the Kolmogorov-Smirnov test. Differences were 
analyzed using OriginPro8.6 (OriginLab, Northampton) or R software (R Foundation for 
Statistical Computing) and one-way ANOVA or Mann-Whitney tests, followed by Bonferroni’s 
post-hoc test, as appropriate. When several cells isolated from the same animal were 
considered, mixed ANOVA followed by Wald c2-test was used. Data are presented as 
means±SE from the indicated number of experiments (animals and cells) per condition. 
 
 
 
 
 
Results 
 
 
Generation and characterization of a novel targeted PLM-Epac1 biosensor  
 
To enable real time measurements of cAMP directly in the NKA/PLM microdomain, we sought 
to develop a targeted version of the highly sensitive FRET biosensor Epac1-camps23. Epac1-
camps is a cytosolic cAMP sensor which contains a cyclic nucleotide binding domain derived 
from Epac1 which is sandwiched between two green fluorescent protein (GFP) mutants, 
namely enhanced cyan (CFP) and yellow fluorescent protein (YFP). In absence of cAMP, CFP 
and YFP are located in close proximity, generating a high degree of FRET signal. Binding of 
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cAMP to Epac1 domain leads to a conformational change in the biosensor molecules which 
brings both fluorophores far apart, decreasing the FRET signal27.  Based on a previously 
developed functional PLM-YFP construct containing a flexible 20 amino acid linker between 
canine PLM and YFP sequence28, we fused our cAMP sensor sequence in a similar way to the 
PLM C-terminus (Figure 1A). When introduced into adult rat ventricular myocytes by 
adenoviral gene transfer (at the multiplicity of infection MOI 300), this targeted biosensor was 
found in the surface membrane and co-localized well with the endogenous NKA a1-subunits, 
similar to native PLM (Supplementary Figure 1A-D). At least some considerable fraction of 
the sensor protein was detected at the cell surface using membrane impermeable biotinylation 
reagent (Supplementary Figure 1B). It could also inhibit NKA activity in transfected cells and 
be co-immunoprecipitated with endogenous cardiomyocyte NKA a1-subunits in both directions 
(Supplementary Figure 2A-C), confirming PLM functionality inside the PLM-Epac1 biosensor. 
Fluorescence in PLM-Epac1 expressing cardiomyocytes showed clear membrane localization 
in outer sarcolemma and a strong intracellular striated pattern which was clearly distinct from 
localization pattern of cytosolic proteins such as GFP and Epac1-camps (Figure 1B,C; 
Supplementary Figure 3). Since this intracellular pattern was highly reminiscent of 
overexpressed junctional sarcoplasmic reticulum (jSR) proteins retained in the biosynthetic 
pathway including perinuclear space and SR29, these areas were excluded from image data 
analysis. Instead of collecting intensity from the whole myocyte, we measured FRET 
responses solely in the region encompassing outer sarcolemma (Figure 1D). Stimulation of 
cells with the b-adrenergic agonist isoproterenol (ISO) led to a rapid decrease in YFP and a 
concomitant increase in CFP fluorescence in the sarcolemmal membrane cell region, 
indicative of a decrease in YFP/CFP ratio and an increase of local cAMP levels (Figure 1D). 
Interestingly, no detectable change of FRET signal could be recorded in the perinuclear region 
with strong overexpression, suggesting that the sensor molecules might be still immature in 
this intracellular compartment and should not be affecting recordings from the functionally 
relevant biosensor pool. Likewise, no detectable change of FRET signal in the membrane 
regions could be observed in cells stimulated with saturating concentrations (10 µmol/L) of 
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protein kinase C activator phorbol 12-myristate 13-acetate (change in FRET 0.09 ± 0.11 %, 
followed by a positive control 10 µmol/L forskolin plus 100 µmol/L IBMX which caused 9.9 ± 
0.6 % decrease of FRET ratio, number of animals/cells was 4/10). 
 
 
 
FRET imaging shows considerable b2-adreneceptor/cAMP signals in the vicinity of PLM  
 
Next, we performed FRET measurements under selective stimulation of b1- and b2-
adrenoceptors (ARs), the major cAMP stimulating adrenergic receptor subtypes expressed in 
cardiomyocytes. Selective b1-AR stimulation performed as previously established3, 5, 25, 30 led 
to comparable cAMP signals in PLM-Epac1 and Epac1-camps expressing myocytes, 
suggesting similar degree of local cAMP increase as in the bulk cytosol (Figure 2A,B). In sharp 
contrast, b2-AR/cAMP responses were nearly doubled in the PLM/NKA microdomain, as 
compared to the cytosol (Figure 2C-E), suggesting close functional association of this receptor 
subtype with PLM. We directly compared the affinities of both biosensors for cAMP and their 
sensitivities to ISO stimulation in intact ARVMs, using a previously established protocol24. 
Interestingly, the affinity of PLM-Epac1 was slightly lower than that of Epac1-camps 
(Supplementary Figure 4A), suggesting that the actual deference in b2-AR/cAMP between 
bulk cytosol and PLM/NKA microdomain might be even greater. Using these sensor calibration 
data, we recalculated FRET values into absolute cAMP concentrations which were 0.73 ± 0.04 
and 2.95 ± 0.41 µM for global (cytosolic) vs. local b2-AR stimulated cAMP, respectively. 
Interestingly, the potencies derived from concentration-response dependencies for ISO 
measured with both sensors were comparable (Supplementary Figure 4B). This suggests 
that b-adrenergic stimulation in general leads to higher cAMP levels at NKA/PLM as compared 
to the bulk cytosol, which is compatible with the idea of privileged receptor – microdomain 
communication previously observed also for the phospholamban microdomain5. 
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Role of PDEs in shaping cAMP signals in the NKA/PLM microdomain 
 
To understand how cAMP dynamics is regulated at the local level, we next studied the effects 
of various PDE inhibitors at basal state and after b1-AR- or b2-AR-selective receptor 
stimulations in healthy cells. The concentrations of PDE inhibitors used have been previously 
established in FRET and PDE activity assays to be selective for the respective PDE families3,5. 
In the absence of prestimulation with b-AR ligands, there were no significant differences found 
in the effects of PDE3 and PDE4 selective inhibitors between bulk cytosol and the NKA/PLM 
microdomain. However, the local contribution of PDE2 was significantly higher in the vicinity 
of PLM (Figure 3). After b1-AR stimulation, all three PDE family inhibitors showed no significant 
differences in FRET responses between the two sensors (Figure 4C). In sharp contrast, the 
contribution of PDE3 was strikingly much more pronounced in the NKA/PLM microdomain after 
b2-AR prestimulation (Figure 4A,B,D). These FRET data correspond to 1.2 ± 0.1 and 31.0 ± 
12.2 µM of global (cytosolic) vs. local cAMP, respectively, after cilostamide application in 
presence of b2-AR stimulation. These data indicate that local cAMP dynamics at PLM is tightly 
controlled by PDE2 at basal state and by PDE3 under b2-AR stimulation, while PDE4 effects 
are present but not significantly different in both locations. 
 
 
 
Heart failure blunts local b2-AR control and alters PDE2/PDE3 balance in the NKA/PLM 
microdomain 
 
Since cardiac disease has been associated with changes in cAMP signaling, we next 
investigated how the NKA/PLM microdomain is affected in the rat model of chronic heart failure 
induced by myocardial infarction. 16 weeks after MI when the chronic failing phenotype has 
been established, ARVMs were isolated and transduced with either cytosolic Epac1-camps or 
with targeted PLM-Epac1 biosensor. At this stage of disease, as expected, b1-AR levels were 
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downregulated whereas the expression of b2-AR, regulatory PKA subunits and adenylyl 
cyclases 5 and 6 were not significantly changed (Supplementary Figure 5). Importantly, heart 
failure did not lead to detectable changes of PLM-Epac1 sensor co-localization with 
endogenous NKA a1-subunit, nor was this co-localization affected by various pharmacological 
treatments used in our study (Supplementary Figure 6). Heart failure also did not visibly affect 
the subcellular localization of the sensor which could be found in intracellular and membrane 
regions expressing caveolin 3 (Supplementary Figure 7,8). Strikingly, heart failure led to a 
loss of the local b2-AR/cAMP signal compartmentation, leading to FRET responses which were 
indistinguishable from those measured in the cytosol (Figure 5A-E). These FRET values 
correspond to 0.8 ± 0.1 and 1.9 ± 0.2 µM of cytosolic vs. local b2-AR stimulated cAMP, 
respectively. Interestingly, while there were no major disease-driven changes in PDE effects 
detected in the cytosol (Supplementary Figure 9), measurements with PLM-Epac1 sensor in 
failing cells after b2-AR stimulation revealed a significant increase in local PDE2 inhibitor 
effects accompanied by a decrease in microdomain-specific PDE3 effects (Figure 5A-D,F). 
Finally, using immunofluorescence, we detected a clear co-localization of PDE3 with 
endogenous PLM which was significantly reduced in heart failure (Supplementary Figure 10). 
Importantly, as expected from the FRET data (see Figures 2E and 5E), b2-AR selective 
stimulation led to a clear phosphorylation of PLM at the Ser68, and this effect was abolished 
in failing cells (Figure 6). 
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Discussion 
  
 
Despite a clear evidence that cAMP modulates cardiac excitation-contraction coupling by 
acting in microdomains associated with sarcolemmal ion channels, local compartmentalized 
cAMP dynamics in their close proximity has not been analyzed before. In this study, we directly 
monitored local cAMP dynamics in the vicinity of NKA by creating a novel PLM-targeted FRET 
biosensor and using it in healthy and failing adult rat ventricular myocytes.  
 
Based on biochemical evidence and co-localization experiments, PLM-Epac1 sensor was 
found in the microdomain of interest and retained functional properties of unmodified PLM in 
terms of physical association with a1-subunits and inhibition of NKA function (see 
Supplementary Figures 1 and 2). Similar to endogenous PLM, it localized in outer sarcolemma, 
while a clear intracellular pattern was also observed which was excluded from the FRET 
analysis (Figure 1B-D; Supplementary Figures 7 and 8). Sarcolemmal localization of the PLM-
Epac1 biosensor was independently confirmed using a biochemical biotinylation assay (see 
Supplementary Figure 1B). However, adenoviral overexpression of the sensor also led to a 
strong perinuclear overexpression artefact and several lower molecular weight band of 
immunoblots (see Supplementary Figure 2) which may result from immature and/or degraded 
sensor protein. Importantly, there was no detectable change in FRET upon stimulation of 
cAMP production when recorded from perinuclear overexpression areas (see Figure 1D), 
suggesting that these irrelevant protein species do not interfere with specific cAMP recordings. 
Another clearly striated and partially dotted intracellular pattern was observed (see Figure 
1B,D, Supplementary Figures 1D, 6A, 7 and 8) which is reminiscent of overexpressed jSR 
proteins retained in the biosynthetic pathway29. Since optical microscopy techniques with its 
resolution close to half of the wavelength of light do not allow to properly resolve T-tubular 
membrane from jSR which are just 10-30 nm apart, we cannot conclude on the localization of 
the biosensor pool or even a part of it in the T-tubular membrane. Silverman et al31 have shown 
that around 75% of endogenous PLM are localized on sarcolemmal membrane while a minor 
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residual fraction might be located in T-tubuli of guinea pig ventricular myocytes. On the other 
hand, rat cardiomyocytes were reported to show somewhat more of a striated or dotted, 
presumably T-tubular staining32-34. Since we could not definitely resolve the exact location of 
the intracellular striated sensor pools, to this end, we analyzed FRET responses from the 
regions of interest encompassing outer sarcolemma. 
 
Interestingly, our FRET-based analysis revealed much stronger b2-AR/cAMP responses in the 
NKA/PLM microdomain, as compared to the bulk cytosol (see Figure 2). This suggests an 
important functional coupling of b2-AR with this microdomain, which, in addition to much more 
abundant b1-AR stimulated cAMP, might critically regulate NKA function. To selectively 
activate b1- and b2-AR subtypes, we used a combination of the unselective b-adrenergic 
agonist ISO together with b1- and b2-AR subtype-selective antagonists CGP20712A and 
ICI118551 which we established to be selective at the respective concentrations using b1- and 
b2-AR knockout mice24. In a previous study, using scanning ion conductance microscopy in 
combination with FRET-based cAMP recordings, we could detect b2-AR/cAMP signals 
originating from functional receptors exclusively located in T-tubules of healthy ARVMs25. This 
T-tubular localization of the b2-AR leads to local cAMP confinement by PKA-dependent 
buffering and activation of PDE4. In contrast, b1-AR as the predominant b-AR subtype was 
evenly distributed across the sarcolemma. b1-AR modulation leads to changes in cAMP signals 
in both cytosolic and sarcolemmal membrane microdomains, to strong contractile responses 
and promotes cardiac remodelling. In contrast, functional b2-ARs are exclusively located in T-
tubules, thereby generating highly localized cAMP responses which do not significantly diffuse 
into the deep cytosol containing sarcoplasmic reticulum and contractile proteins but may 
protect from pathological remodelling25, 35. Therefore, one may expect a functional interaction 
of b2-AR with NKA/PLM. It is also well documented that b2-ARs are localized in caveolin rich 
membrane domains which may include sarcolemmal caveolae36. Obviously, it is difficult to 
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conclude for our data whether PLM is co-localized with T-tubuli. However, FRET recordings 
indicate a close functional association of b2-AR/cAMP pools with the NKA/PLM mocrodomain. 
 
It is tempting to speculate that b2-AR could also play a cardioprotective role by inducing a local 
pool of cAMP which leads to phosphorylation of PLM and protection from Ca2+ overload. 
However, in chronic heart failure, this cAMP microdomain becomes disrupted (see Figure 5E) 
which may limit the potentially beneficial effects of b2-AR. Previously, Juel and colleagues 
showed that b2-AR activation modulates NKA activity in human skeletal muscle37, although 
PLM phosphorylation was not examined in this study. Two other reports38, 39 showed that 
pharmacological b2-AR agonists (terbutaline and formoterol) both increased PLM Ser68 
phosphorylation in human skeletal muscle. Here, we report for the first time that b2-AR 
signaling modulates local cAMP gradients around the NKA/PLM microdomain, leading to PKA-
mediated PLM phosphorylation in cardiac myocytes which is changed in disease. Our FRET 
data go in line with immunoblot analysis which shows that selective b2-AR stimulation leads to 
an increase of PLM phosphorylation, and that this effect is clearly abolished in heart failure 
(see Figure 6). The drop of b2-AR/cAMP signal in the vicinity of NKA/PLM could be, at least in 
part, a result of b2-AR redistribution from T-tubules to detubulated membrane areas which has 
been previously described for failing cardiomyocytes isolated the same MI-induced disease 
model25.  Potentially, detubulation could promote also PDE3 redistribution, thereby affecting 
local cAMP degradation. 
 
Equally important could be changes in PDE composition of the NKA/PLM microdomain 
detected in this study. By analyzing the effects of the selective inhibitors for the major 
cardiomyocyte cAMP hydrolyzing PDEs (2, 3 and 4), we found that the NKA/PLM microdomain 
is under stringent PDE2 dependent control at basal state, while after b2-AR stimulation, PDE3 
becomes dominant (see Figures 3 and 4). This is comparable with the data from adult mouse 
cardiomyocytes obtained using a targeted version of the Epac1-camps sensor localized in the 
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caveolin-rich membrane microdomains including T-tubules (pmEpac)3. Using 
immunofluorescence, significant co-localization of PDE3A with endogenous PLM could be 
observed, which may result from PDE3A association with sarcolemma and SR membrane, 
with a clear reduction in heart failure (see Supplementary Figure 10). Likewise, functional effect 
of the PDE3 inhibitor cilostamide on cAMP levels in the NKA/PLM microdomain was 
dramatically reduced in failing cells (see Figure 5C,D,F). Instead, the local effect of PDE2 was 
significantly increased (see Figure 5A,B,F). This important PDE has been previously shown to 
be upregulated at the mRNA and protein level in various heart failure models40, and seems to 
affect especially the local microdomain signaling (Figure 7), while no significant disease-driven 
alterations could be detected in the bulk cytosol (Supplementary Figure 9). Previously, using 
an early disease model of compensated cardiac hypertrophy induced by transverse aortic 
constriction in pmEpac expressing mice, we uncovered a PDE2 and PDE3 redistribution 
between b1- and b2-AR-associated caveolar and non-caveolar membrane microdomains. In 
this case, PDE3 as the predominant PDE family at the b2-AR was substituted by PDE2, leading 
to changes in cGMP/cAMP cross-talk engaged by atrial natriuretic peptide receptors3. 
Obviously, a similar change in PDE repertoire in the NKA/PLM microdomain can be now 
detected also in a chronic rat heart failure model (see Figure 5). This change of the 
microdomain-specific PDE composition should definitely affect the rates of cAMP hydrolysis 
resulting in a change of responsiveness to b2-AR stimulation. The modulation of the local cAMP 
response by cGMP associated with atrial and brain natriuretic peptide signaling is unlikely to 
play a role in this decompensated late disease model because of the desensitization of their 
common NPR1 receptor which is typical for chronic heart failure41. 
 
In summary, we provide the first direct visualization of local cAMP signaling at a sarcolemmal 
cardiomyocyte ion channel regulated in a microdomain formed around the NKA/PLM complex. 
FRET based live cell imaging indicates tight regulation of this microdomain by the b2-AR and 
local pools of PDE3 and its dramatic alteration in heart failure. This knowledge could provide 
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a molecular basis for novel therapeutic strategies to prevent disease-associated sodium 
overload and impaired excitation-contraction coupling. 
 
  
 
 
 
Acknowledgments  
 
We thank Tobias Goldak and Karina Schlosser for ARVM isolation and technical assistance.  
 
 
Conflict of Interest 
None declared. 
 
Funding  
The work was supported by the Deutsche Forschungsgemeinschaft (IRTG1816 to V.O.N. and 
M.J.S.), Wellcome Trust (109604/Z/15/Z to D.P.), British Heart Foundation (RG/12/18/30088 
to J.G.) and the Gertraud und Heinz-Rose Stiftung (to V.O.N.). 
 
 
References  
 
1. Perino A, Ghigo A, Scott JD, Hirsch E. Anchoring proteins as regulators of signaling pathways. 
Circ Res 2012;111:482-492. 
2. Perera RK, Nikolaev VO. Compartmentation of cAMP signalling in cardiomyocytes in health 
and disease. Acta Physiol (Oxf) 2013;207:650-662. 
3. Perera RK, Sprenger JU, Steinbrecher JH, Hubscher D, Lehnart SE, Abesser M, Schuh K, El-
Armouche A, Nikolaev VO. Microdomain switch of cGMP-regulated phosphodiesterases leads 
to ANP-induced augmentation of beta-adrenoceptor-stimulated contractility in early cardiac 
hypertrophy. Circ Res 2015;116:1304-1311. 
4. Rochais F, Vandecasteele G, Lefebvre F, Lugnier C, Lum H, Mazet JL, Cooper DM, 
Fischmeister R. Negative feedback exerted by cAMP-dependent protein kinase and cAMP 
phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac myocytes: an in vivo 
study using adenovirus-mediated expression of CNG channels. J Biol Chem 2004;279:52095-
52105. 
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvy221/5079901 by U
niversity of Birm
ingham
 user on 12 Septem
ber 2018
 
 
16 
 
5. Sprenger JU, Perera RK, Steinbrecher JH, Lehnart SE, Maier LS, Hasenfuss G, Nikolaev VO. 
In vivo model with targeted cAMP biosensor reveals changes in receptor-microdomain 
communication in cardiac disease. Nat Commun 2015;6:6965. 
6. Skou JC. The influence of some cations on an adenosine triphosphatase from peripheral 
nerves. Biochim Biophys Acta 1957;23:394-401. 
7. Blaustein MP. Sodium ions, calcium ions, blood pressure regulation, and hypertension: a 
reassessment and a hypothesis. Am J Physiol 1977;232:C165-173. 
8. Bers DM, Despa S. Na+ transport in cardiac myocytes; Implications for excitation-contraction 
coupling. IUBMB Life 2009;61:215-221. 
9. Pogwizd SM. Clinical potential of sodium-calcium exchanger inhibitors as antiarrhythmic 
agents. Drugs 2003;63:439-452. 
10. Verdonck F, Volders PG, Vos MA, Sipido KR. Intracellular Na+ and altered Na+ transport 
mechanisms in cardiac hypertrophy and failure. J Mol Cell Cardiol 2003;35:5-25. 
11. Pieske B, Maier LS, Piacentino V, 3rd, Weisser J, Hasenfuss G, Houser S. Rate dependence 
of [Na+]i and contractility in nonfailing and failing human myocardium. Circulation 
2002;106:447-453. 
12. Liu T, O'Rourke B. Enhancing mitochondrial Ca2+ uptake in myocytes from failing hearts 
restores energy supply and demand matching. Circ Res 2008;103:279-288. 
13. Palmer CJ, Scott BT, Jones LR. Purification and complete sequence determination of the 
major plasma membrane substrate for cAMP-dependent protein kinase and protein kinase C 
in myocardium. J Biol Chem 1991;266:11126-11130. 
14. Bogaev RC, Jia LG, Kobayashi YM, Palmer CJ, Mounsey JP, Moorman JR, Jones LR, Tucker 
AL. Gene structure and expression of phospholemman in mouse. Gene 2001;271:69-79. 
15. Wetzel RK, Sweadner KJ. Phospholemman expression in extraglomerular mesangium and 
afferent arteriole of the juxtaglomerular apparatus. Am J Physiol Renal Physiol 
2003;285:F121-129. 
16. Crambert G, Fuzesi M, Garty H, Karlish S, Geering K. Phospholemman (FXYD1) associates 
with Na,K-ATPase and regulates its transport properties. Proc Natl Acad Sci U S A 
2002;99:11476-11481. 
17. Khafaga M, Bossuyt J, Mamikonian L, Li JC, Lee LL, Yarov-Yarovoy V, Despa S, Bers DM. 
Na(+)/K(+)-ATPase E960 and phospholemman F28 are critical for their functional interaction. 
Proc Natl Acad Sci U S A 2012;109:20756-20761. 
18. Walaas SI, Czernik AJ, Olstad OK, Sletten K, Walaas O. Protein kinase C and cyclic AMP-
dependent protein kinase phosphorylate phospholemman, an insulin and adrenaline-regulated 
membrane phosphoprotein, at specific sites in the carboxy terminal domain. Biochem J 
1994;304 ( Pt 2):635-640. 
19. Han F, Bossuyt J, Despa S, Tucker AL, Bers DM. Phospholemman phosphorylation mediates 
the protein kinase C-dependent effects on Na+/K+ pump function in cardiac myocytes. Circ 
Res 2006;99:1376-1383. 
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvy221/5079901 by U
niversity of Birm
ingham
 user on 12 Septem
ber 2018
 
 
17 
 
20. Fuller W, Howie J, McLatchie LM, Weber RJ, Hastie CJ, Burness K, Pavlovic D, Shattock MJ. 
FXYD1 phosphorylation in vitro and in adult rat cardiac myocytes: threonine 69 is a novel 
substrate for protein kinase C. Am J Physiol Cell Physiol 2009;296:C1346-1355. 
21. Despa S, Tucker AL, Bers DM. Phospholemman-mediated activation of Na/K-ATPase limits 
[Na]i and inotropic state during beta-adrenergic stimulation in mouse ventricular myocytes. 
Circulation 2008;117:1849-1855. 
22. Boguslavskyi A, Pavlovic D, Aughton K, Clark JE, Howie J, Fuller W, Shattock MJ. Cardiac 
hypertrophy in mice expressing unphosphorylatable phospholemman. Cardiovasc Res 
2014;104:72-82. 
23. Nikolaev VO, Bunemann M, Hein L, Hannawacker A, Lohse MJ. Novel single chain cAMP 
sensors for receptor-induced signal propagation. J Biol Chem 2004;279:37215-37218. 
24. Börner S, Schwede F, Schlipp A, Berisha F, Calebiro D, Lohse MJ, Nikolaev VO. FRET 
measurements of intracellular cAMP concentrations and cAMP analog permeability in intact 
cells. Nat Protoc 2011;6:427-438. 
25. Nikolaev VO, Moshkov A, Lyon AR, Miragoli M, Novak P, Paur H, Lohse MJ, Korchev YE, 
Harding SE, Gorelik J. Beta2-adrenergic receptor redistribution in heart failure changes cAMP 
compartmentation. Science 2010;327:1653-1657. 
26. Lyon AR, MacLeod KT, Zhang Y, Garcia E, Kanda GK, Lab MJ, Korchev YE, Harding SE, 
Gorelik J. Loss of T-tubules and other changes to surface topography in ventricular myocytes 
from failing human and rat heart. Proc Natl Acad Sci U S A 2009;106:6854-6859. 
27. Schobesberger S, Tokar S, Wright P, Bhargava A, Glukhov AV, Poulet C, Buzuk A, Monszpart 
A, Sikkel MB, Harding SE, Nikolaev VO, Lyon AR, Gorelik J. T-tubule remodelling disturbs 
localised β2-adrenergic signalling in rat ventricular myocyte during the progression of heart 
failure. Cardiovasc Res 2017;in press. 
28. Tulloch LB, Howie J, Wypijewski KJ, Wilson CR, Bernard WG, Shattock MJ, Fuller W. The 
inhibitory effect of phospholemman on the sodium pump requires its palmitoylation. J Biol 
Chem 2011;286:36020-36031. 
29. Sleiman NH, McFarland TP, Jones LR, Cala SE. Transitions of protein traffic from cardiac ER 
to junctional SR. J Mol Cell Cardiol 2015;81:34-45. 
30. Nikolaev VO, Bünemann M, Schmitteckert E, Lohse MJ, Engelhardt S. Cyclic AMP imaging in 
adult cardiac myocytes reveals far-reaching beta1-adrenergic but locally confined beta2-
adrenergic receptor-mediated signaling. Circ Res 2006;99:1084-1091. 
31. Silverman B, Fuller W, Eaton P, Deng J, Moorman JR, Cheung JY, James AF, Shattock MJ. 
Serine 68 phosphorylation of phospholemman: acute isoform-specific activation of cardiac 
Na/K ATPase. Cardiovasc Res 2005;65:93-103. 
32. Cheung JY, Zhang XQ, Song J, Gao E, Rabinowitz JE, Chan TO, Wang J. Phospholemman: a 
novel cardiac stress protein. Clin Transl Sci 2010;3:189-196. 
33. Wypijewski KJ, Howie J, Reilly L, Tulloch LB, Aughton KL, McLatchie LM, Shattock MJ, 
Calaghan SC, Fuller W. A separate pool of cardiac phospholemman that does not regulate or 
associate with the sodium pump: multimers of phospholemman in ventricular muscle. J Biol 
Chem 2013;288:13808-13820. 
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvy221/5079901 by U
niversity of Birm
ingham
 user on 12 Septem
ber 2018
 
 
18 
 
34. Zhang XQ, Qureshi A, Song J, Carl LL, Tian Q, Stahl RC, Carey DJ, Rothblum LI, Cheung JY. 
Phospholemman modulates Na+/Ca2+ exchange in adult rat cardiac myocytes. Am J Physiol 
Heart Circ Physiol 2003;284:H225-233. 
35. Xiao RP. Beta-adrenergic signaling in the heart: dual coupling of the beta2-adrenergic 
receptor to G(s) and G(i) proteins. Sci STKE 2001;2001:re15. 
36. Head BP, Patel HH, Roth DM, Lai NC, Niesman IR, Farquhar MG, Insel PA. G-protein-
coupled receptor signaling components localize in both sarcolemmal and intracellular 
caveolin-3-associated microdomains in adult cardiac myocytes. J Biol Chem 2005;280:31036-
31044. 
37. Juel C, Hostrup M, Bangsbo J. The effect of exercise and beta2-adrenergic stimulation on 
glutathionylation and function of the Na,K-ATPase in human skeletal muscle. Physiol Rep 
2015;3. 
38. Hostrup M, Kalsen A, Onslev J, Jessen S, Haase C, Habib S, Ortenblad N, Backer V, 
Bangsbo J. Mechanisms underlying enhancements in muscle force and power output during 
maximal cycle ergometer exercise induced by chronic beta2-adrenergic stimulation in men. J 
Appl Physiol (1985) 2015;119:475-486. 
39. Kalsen A, Hostrup M, Backer V, Bangsbo J. Effect of formoterol, a long-acting beta2-
adrenergic agonist, on muscle strength and power output, metabolism, and fatigue during 
maximal sprinting in men. Am J Physiol Regul Integr Comp Physiol 2016;310:R1312-1321. 
40. Mehel H, Emons J, Vettel C, Wittkopper K, Seppelt D, Dewenter M, Lutz S, Sossalla S, Maier 
LS, Lechene P, Leroy J, Lefebvre F, Varin A, Eschenhagen T, Nattel S, Dobrev D, 
Zimmermann WH, Nikolaev VO, Vandecasteele G, Fischmeister R, El-Armouche A. 
Phosphodiesterase-2 Is up-regulated in human failing hearts and blunts beta-adrenergic 
responses in cardiomyocytes. J Am Coll Cardiol 2013;62:1596-1606. 
41. Kuhn M. Structure, regulation, and function of mammalian membrane guanylyl cyclase 
receptors, with a focus on guanylyl cyclase-A. Circ Res 2003;93:700-709. 
 
 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvy221/5079901 by U
niversity of Birm
ingham
 user on 12 Septem
ber 2018
 
 
19 
 
Figure legends 
 
 
Figure 1. Generation of a targeted PLM-Epac1 biosensor. (A) Schematic representation of 
the PLM-Epac1 sensor construct that includes full-length phospholemman (PLM) fused via a 
flexible linker to the parental cytosolic cAMP biosensor Epac1-camps comprised of the cAMP-
binding domain sandwiched between enhanced yellow (YFP) and enhanced cyan (CFP) 
fluorescent proteins. (B) Representative confocal images of adult rat ventricular myocytes 
(ARVMs) transduced with adenoviral constructs to express Epac1-camps or PLM-Epac1. 
Fluorescence in YFP and CFP channels reveals sarcolemmal and partially striated intracellular 
membrane localization pattern for PLM-Epac1, as compared to the cytosolic Epac1-camps. 
TM, transmission image. See Supplementary Figure 3 for autofluorescence image. (C) 
Representative confocal image (n=10) showing live cell membrane staining of PLM-Epac1 
expressing ARVM. Scale bar, 2 µm. (D) Representative FRET recording (n=10) of a PLM-
Epac1 expressing ARVM stimulated with the b-adrenergic agonist isoproterenol (ISO, 100 
nmol/L). Left, YFP and CFP intensities measured in a red-marked membrane region of interest 
to exclude strongly fluorescent perinuclear overexpression show concomitant changes, 
indicative of a decreasing YFP/CFP FRET ratio (here normalized to the basal ratio values) 
which represents an increase of local cAMP levels upon ISO treatment. In contrast, no 
detectable FRET change could be observed in perinuclear location (marked black) with sensor 
overexpression (right). Scale bars, 10 µm.  
 
Figure 2. Strong local β₂-AR/cAMP signals in the PLM/NKA microdomain. (A,B) 
Representative FRET traces for Epac1-camps and PLM-Epac1 expressing ARVMs upon β₁-
AR-selective stimulation (100 nmol/L ISO plus 50 nmol/L of the β₂-AR blocker ICI118551). 
(C,D) Representative FRET traces for β₂-AR-selective stimulation (100 nmol/L ISO plus 100 
nmol/L of the β₁-AR blocker CGP20712A). Maximal stimulation of cAMP was subsequently 
achieved by the PDE2 selective inhibitor (BAY 60-7550, 100 nmol/L used in C and D, see 
Figure 4), the unselective PDE inhibitor IBMX (100 μmol/L) and the adenylyl cyclase activator 
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forskolin (10 μmol/L). (E) Quantification of FRET responses to selective β₁- and β2-AR 
stimulations shown in A-D. Number of cells (n) and hearts (N) per condition were as follows -  
n/N=40/6 and n/N=33/6 for β1-AR and n/N=31/9 and n/N=38/8 for β2-AR, respectively. * — 
significant difference, P<0.05 by mixed ANOVA followed by Wald c2-test.   
 
Figure 3.  PDE contributions to cAMP hydrolysis under basal conditions. Representative 
FRET traces recorded in ARVMs expressing either cytosolic (A) or NKA/PLM microdomain 
specific (B) biosensor upon PDE2 inhibition with 100 nmol/L BAY 60-7550, followed by 100 
µmol/L of the unselective PDE inhibitor IBMX and by 100 nmol/L ISO and 10 µmol/L forskolin 
to achieve maximal stimulation. (C) Quantification of the FRET ratio change induced by the 
specific PDE inhibitors (10 µmol/L cilostamide for PDE3 and 10 µmol/L rolipram for PDE4 were 
used, respectively) related to the maximum stimulation uncovered PDE2 as the PDE family 
crucial for confining the PLM/NKA compartment from the bulk cytosol at basal state. Means ± 
SE, number of cells (n) and hearts (N) per condition were as follows - n/N=10/4 and n/N=10/4 
for PDE2, n/N=12/4 and n/N=24/6 for PDE3, and n/N=12/5 and n/N=12/5 for PDE4, 
respectively. * — significant differences, P<0.05 by Mann-Whitney test. n.s. - not significant, 
P˃0.05 by mixed ANOVA followed by Wald c2-test.  
 
Figure 4. PDE regulation of cytosolic and local cAMP levels under subtype specific β-
AR stimulations. Representative FRET ratio traces for Epac1-camps (A) and PLM-Epac1 (B) 
expressing ARVMs recorded during selective β₂-AR stimulation with 100 nmol/L ISO plus 50 
nmol/L CGP20712A followed by the PDE3 inhibitor cilostamide (Cilo, 10 µmol/L) and the 
unselective PDE inhibitor IBMX (100 µmol/L). Forskolin (10 µmol/L) was used to fully stimulate 
the sensors. (C) Quantification of the PDE inhibitor responses in cells with prestimulated β1-
AR. 100 nmol/L BAY 60-7550 and 10 µmol/L rolipram were used to inhibit PDE2 and PDE4, 
respectively. Shown are means ± SE, number of cells (n) and hearts (N) per condition were as 
follows - n/N=13/4 and n/N=14/5 for PDE2, n/N=13/4 and n/N=16/5 for PDE3, and n/N=19/3 
and n/N=15/9 for PDE4, respectively. (D) Quantification of the PDE inhibitor responses in cells 
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with prestimulated β₂-AR. Means ± SE, number of cells (n) and hearts (N) per condition were 
as follows - n/N=12/4 and n/N=13/4 for PDE2, n/N=11/4 and n/N=16/4 for PDE3, and n/N=13/4 
and n/N=14/4 for PDE4, respectively. * — significant differences, P<0.05 by mixed ANOVA 
followed by Wald c2-test. n.s. - not significant, P˃0.05 by the same test.    
 
Figure 5. Changes in local cAMP dynamics at PLM in heart failure. (A-D) Representative 
FRET traces for ARVMs isolated from either age-matched controls (AMC) or from rats with 
chronic heart failure 16 weeks after MI and transduced to express PLM-Epac1 sensor. Cells 
were first stimulated with 100 nmol/L ISO plus 100 nmol/L CGP20712A to activate β₂-AR 
followed by the PDE2 and PDE3 inhibitors and forskolin. (E) β₂-AR stimulation shows a 
significantly attenuated cAMP response in the microdmain, indicating a loss of β₂-AR/cAMP 
compartmentation. Data from cells expressing the cytosolic sensor Epac1-camps are also 
provided for comparison. Shown are means ± SE, number of cells (n) and hearts (N) per 
condition were as follows - n/N=27/4 and n/N=26/4 for AMC, and n/N=23/4 and n/N=27/4 for 
MI groups, respectively. (F) Data analysis for the experiments shown in A-D. In heart failure, 
there is a pronounced increase in local PDE2 and a decrease in local PDE3 inhibitor effects. 
Compound concentrations were as in Figure 4. Means±SE, number of cells (n) and hearts (N) 
per condition were as follows - n/N=7/4 and n/N=6/3 for PDE2, and n/N=12/4 and n/N=9/3 for 
PDE3, respectively. * — significant differences, P<0.05 by mixed ANOVA followed by Wald c2-
test.   
 
Figure 6. Immunoblot analysis of PLM phosphorylation. (A) Representative immunoblots 
for ARVMs isolated from either controls (AMC) or from rats with chronic heart failure after MI. 
Cells were stimulated for 5 min with 100 nmol/L ISO plus 100 nmol/L CGP20712A to selectively 
activate β₂-AR. PLM phosphorylation was analyzed using a Ser68 phosphoantibody. In healthy 
cells, β₂-AR stimulates PLM phosphorylation, this effect is blunted in heart failure. Data 
analysis is in (B). Means±SE, number of blots/hearts were 6/3 and 5/3 for control and 
stimulated groups, respectively. * — significant difference, P<0.05 by one-way ANOVA.     
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Figure 7. Schematics depicting local regulation of cAMP in the NKA/PLM microdomain 
and its changes in heart failure. In healthy ARVMs, NKA/PLM is in close functional proximity 
to the β₂-AR and PDE3. In disease, receptor and PDE redistribution disrupts the proper β₂-AR 
signaling to cAMP/PKA/PLM. Local increase of PDE2 mediated effects and a decrease of 
PDE3 co-localization with the microdomain can be detected in disease. 
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Figure 1 (Bastug-Özel et al.)
A
B                                             C
D
0 50 100 150
219.2
219.6
220.0
Time (s)
C
F
P
 (
a
.U
.)
35
36
37
38
ISO
Y
F
P
 (
a
.U
.)
Epac1-camps PLM-Epac1
YFP
CFP
TM
0 50 100 150
0.92
0.94
0.96
0.98
1.00
F
R
E
T
 r
a
tio
 Y
F
P
/C
F
P
 (
n
o
rm
.)
Time (s)
membrane perinuclear
PLM-Epac1   Membrane      Overlay
0 50 100 150
0.92
0.94
0.96
0.98
1.00
F
R
E
T
 r
a
tio
 Y
F
P
/C
F
P
 (
n
o
rm
.)
Time (s)
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvy221/5079901 by U
niversity of Birm
ingham
 user on 12 Septem
ber 2018
Figure 2 (Bastug-Özel et al.)
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Figure 3 (Bastug-Özel et al.)
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Figure 4 (Bastug-Özel et al.)
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Figure 5 (Bastug-Özel et al.)
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Figure 6 (Bastug-Özel et al.)
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Figure 7 (Bastug-Özel et al.)
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